Detalles de la búsqueda
1.
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.
Br J Dermatol
; 189(2): 161-169, 2023 07 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37120722
2.
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Lancet
; 394(10201): 831-839, 2019 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31402114
3.
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 82(4): 936-945, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31809827
4.
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
N Engl J Med
; 373(2): 136-44, 2015 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26154787
5.
Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
J Drugs Dermatol
; 17(8): 873-879, 2018 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30124726
6.
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
J Drugs Dermatol
; 17(8): 826-832, 2018 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30124721
7.
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.
J Pharmacokinet Pharmacodyn
; 45(4): 523-535, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29549540
8.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
J Am Acad Dermatol
; 76(3): 405-417, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28057360
9.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
J Am Acad Dermatol
; 76(3): 418-431, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28057361
10.
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.
J Pharmacokinet Pharmacodyn
; 44(5): 437-448, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28634654
11.
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).
Ann Rheum Dis
; 75(11): 1984-1988, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27098404
12.
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
J Am Acad Dermatol
; 73(4): 594-603, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26259989
13.
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
J Dermatolog Treat
; 33(4): 2317-2324, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34348574
14.
Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials.
Dis Colon Rectum
; 54(5): 570-8, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21471758
15.
Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms.
Value Health
; 14(1): 177-83, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21211500
16.
Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis.
Pain Med
; 12(8): 1223-30, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21810165
17.
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
J Dermatolog Treat
; 32(5): 484-491, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31613178
18.
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
Clin Pharmacol Ther
; 109(1): 131-139, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865226
19.
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
J Clin Pharmacol
; 58(5): 613-627, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29341192
20.
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
JAMA Dermatol
; 154(6): 676-683, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29799960